Life Sciences Synthetic Biology Platform Software sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Synthetic Biology Platform Software
1.1 - About Life Sciences Synthetic Biology Platform Software sector
Companies in the Life Sciences Synthetic Biology Platform Software category provide computational and automation systems that power design–build–test–learn workflows for engineered cells and microbes. Their platforms unify sequence design, experiment orchestration, lab data capture, and analytics to streamline strain optimization and pathway engineering. By integrating biofoundry automation and cloud data infrastructure, they help customers accelerate R&D, standardize protocols, and move candidates from bench to pilot scale more predictably.
Offerings typically include DNA design and CAD environments with constraint-based modeling, AI-driven sequence and pathway optimization, and CRISPR library design. Vendors deliver biofoundry automation software for liquid handlers and microfluidics, LIMS tailored to synthetic biology, and high-throughput screening analytics with experiment versioning. Many add bioprocess optimization dashboards, metabolic simulation, and cloud lab APIs, alongside integrations to ELN, MES, and data lakes to ensure traceability, compliance, and scalable data management.
Primary customers include biotech R&D teams, pharmaceutical process development groups, and industrial biotech manufacturers. These platforms shorten strain engineering cycles, increase titers and yields, reduce experimental costs through automated workflows, and improve reproducibility and data governance. They also accelerate tech transfer from discovery to pilot plant, strengthen compliance and auditability, and provide decision support for portfolio prioritization across engineered pathways and cell lines.
2. Buyers in the Life Sciences Synthetic Biology Platform Software sector
2.1 Top strategic acquirers of Life Sciences Synthetic Biology Platform Software companies
Amyris
- Description: Provider of consumer products and science-based ingredients, offering health and wellness, clean beauty, personal care, and flavor and fragrance ingredients that are sold through e-commerce, retail channels and directly to formulators, distributors and joint-venture partners.
- Key Products:
- Zero Calorie Sugarcane-Derived Sweetener: Fermented from sugarcane to 95 % purity, delivering a zero-calorie sweet taste without bitter aftertaste and produced sustainably at scale
- Bioscience Fermentation Platform: Proprietary microbial engineering process converting plant sugars into hydrocarbon molecules, enabling large-scale production of renewable specialty ingredients for multiple consumer markets
- No Compromise Ingredient Portfolio: Range of sustainable health, beauty, flavor and fragrance molecules supplied to brand partners, offering high performance with reduced environmental impact.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Synthetic Biology Platform Software sector
M&A buyer group 1: LIMS
Elemental Machines
- Type: N/A
- Employees: ●●●●●
- Description: Provider of an intelligent operations platform that integrates IoT sensors, custom hardware and software to give labs, biopharma and manufacturing sites real-time monitoring, predictive analytics and actionable insights, transforming equipment oversight, compliance and operational efficiency from reactive to proactive.
- Key Products:
- Intelligent Operations Platform: IoT-connected hardware, sensors and software collect high-sample-rate data, unify physical-digital worlds and provide actionable insights that simplify, optimize and augment laboratory and manufacturing operations
- AI-Driven Predictive Analytics: Contextual anomaly detection, custom AI models and proactive maintenance insights forecast issues, reduce downtime and extend equipment lifespan while displaying real-time data in user-friendly dashboards
- Freezer Monitoring Solutions: Continuous cold-storage monitoring with alerts ensures freezer health, protects samples during off-hours and safeguards compliance for life-science laboratories
- Custom Dashboards: Highly configurable dashboards let users combine multiple data sources, monitor key metrics in real-time, tailor insights to workflows and simplify data-driven decision-making across environmental and utilization parameters.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Synthetic Biology Platform Software sector
3.1 - Buyout funds in the Life Sciences Synthetic Biology Platform Software sector
2.2 - Strategic buyer groups for Life Sciences Synthetic Biology Platform Software sector
4 - Top valuation comps for Life Sciences Synthetic Biology Platform Software companies
4.2 - Public trading comparable groups for Life Sciences Synthetic Biology Platform Software sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.